Tonix Pharmaceuticals Holding Corp. — FY2017 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2017, compared with FY2016. Tonix is a clinical-stage biopharmaceutical company with no marketed products or product revenue. Its lead candidate, Tonmya (TNX-102 SL), is in Phase 3 development for PTSD; the company is also developing it for agitation in Alzheimer’s disease and maintains earlier-stage drug and biodefense programs.
Financial results and liquidity
- Revenue: No product revenue was generated. The filing reports no commercial products available for sale.
- Profit and expenses: Net loss was $21.1 million, or $3.17 per share, versus a $38.8 million loss, or $15.41 per share, in FY2016. Operating expenses were $21.3 million: research and development of $13.3 million and general and administrative expenses of $7.9 million. Interest income was $0.2 million.
- Cash flow: Cash used in operations was $19.1 million, compared with $37.3 million in FY2016. Financing provided $18.5 million net, primarily from common-stock sales. Investing activities provided $7.2 million, principally from maturities of marketable securities.
- Cash and liquidity: At year-end, cash and cash equivalents were $25.5 million, restricted cash was $0.1 million, and working capital was $24.3 million. Marketable securities were zero, down from $7.2 million in 2016. Current liabilities were $2.1 million; total liabilities were $2.1 million. No material interest-bearing debt is identified in the supplied filing text.
- Margins: Not meaningful because the company had no product revenue.
- Commitments: Contract research and development commitments totaled approximately $11.2 million at year-end; future minimum lease payments were $0.6 million.
Material changes versus FY2016
- Research and development expense declined 53% to $13.3 million, mainly following the discontinuation of the fibromyalgia and episodic tension-type headache programs and fewer active trials.
- General and administrative expense declined 23% to $7.9 million, primarily due to lower personnel and professional-services costs.
- Net loss narrowed by $17.7 million and operating cash use fell by $18.2 million, reflecting reduced spending rather than product revenue.
- Net financing proceeds were $18.5 million in 2017 versus $20.5 million in 2016. The company completed an April 2017 public offering and ATM sales, and entered a Lincoln Park agreement providing for up to $15 million of stock purchases, subject to terms and limits.
- Shares outstanding increased from 3.9 million at December 31, 2016 to 7.8 million at December 31, 2017. A 1-for-10 reverse split took effect in March 2017; reported share and per-share amounts reflect the split.
Outlook, commentary, and principal risks
- Management said available cash was expected to fund planned operations through the end of 2018, but also stated that resources were insufficient for the one-year period from the March 9, 2018 filing date. The auditor’s report includes an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern.
- Tonix reported that the Phase 3 HONOR PTSD study was underway, targeting approximately 550 participants, with a planned interim analysis and an independent data monitoring committee. FDA discussions indicated that a single-study NDA could be possible if HONOR results were statistically persuasive; this is not an approval or assurance of success. No HONOR efficacy results are provided in the filing.
- The FDA granted Tonmya Breakthrough Therapy designation for PTSD. The designation may facilitate development and review but does not change approval standards or guarantee approval.
- Management planned to submit an IND in March 2018 for TNX-102 SL in Alzheimer’s agitation. TNX-601 and TNX-801 were pre-IND; TNX-301 was an IND candidate with planning underway; TNX-701 remained in nonclinical development.
- Key risks include clinical-trial failure or delay, regulatory and manufacturing hurdles, reliance on outside manufacturers and research organizations, competition, uncertain reimbursement and market acceptance, intellectual-property challenges, and the need for additional capital. Further financing may dilute shareholders; failure to obtain funding could force reductions or delays in development.
- Unusual items include the full valuation allowance against deferred tax assets, meaning the 2017 U.S. tax-law changes were not expected to affect net tax expense or financial position, and the reverse stock split. The filing reports no legal proceedings believed likely to have a material adverse effect.
Important facts for investors to verify
- Subsequent cash position, financing access, and operating runway, given the going-concern qualification and management’s differing runway statements.
- HONOR trial enrollment, interim-analysis outcome, final results, and whether the FDA accepts a single-study NDA package.
- Actual spending against the $11.2 million research and development commitment and the timing of additional funding needs.
- Current share count, potential dilution from equity plans, warrants, and the Lincoln Park purchase agreement.
- Regulatory progress and funding priorities for the Alzheimer’s agitation and other pipeline programs.